Young adults who turn to cannabis face startling odds when it comes to their hearts. A major study released this year tracked more than 4.6 million people. It found those under 50 who used the drug but started with clean bills of health suffered heart attacks at more than six times the rate of nonusers. The risks didn’t stop there.
Fourfold jumps in ischemic strokes. Double the chance of heart failure. And a threefold increase in the combined threat of cardiovascular death, heart attack or stroke. All this over roughly three years of follow-up. The data come from electronic medical records analyzed through a global research network called TriNetX. Participants showed normal blood pressure, healthy LDL cholesterol, no diabetes and no tobacco habit at the start.
The American College of Cardiology highlighted these results in March 2025. Lead author Ibrahim Kamel, MD, a clinical instructor at Boston University and resident at St. Elizabeth Medical Center, didn’t mince words. “Asking about cannabis use should be part of clinicians’ workup to understand patients’ overall cardiovascular risk, similar to asking about smoking cigarettes.” He added that policy makers should issue fair warnings.
But one study rarely settles such a charged issue. So researchers paired the retrospective analysis with a sweeping meta-analysis. They reviewed 12 earlier papers that together covered more than 75 million people. Average age hovered around 41 where reported. Ten studies came from the United States, one from Canada and one from India. Quality ratings landed in the moderate-to-good range.
Pooled together the data showed cannabis users carried a 50 percent higher risk of heart attack. Seven of the 12 papers had already pointed to a clear link. Four found none. One hinted at a slight protective effect that vanished in the larger view. Still the combined signal held. Active users proved 1.5 times as likely to have a heart attack.
These numbers land at a moment when cannabis enjoys broader legal access than ever. Millions consume it recreationally or for perceived medical relief. Yet the cardiovascular picture grows darker with each fresh examination. A separate analysis published in the journal Heart in June 2025 examined 24 studies involving some 200 million adults mostly between 19 and 59. That work reported a doubled risk of dying from cardiovascular disease among users. Heart attack risk climbed 29 percent. Stroke risk rose 20 percent.
Senior author Émilie Jouanjus, an associate professor of pharmacology at the University of Toulouse in France, noted the patients landing in hospitals often looked surprisingly young. Many lacked prior heart trouble or obvious risk factors. The editorial that ran alongside the Heart paper pulled no punches. It likened cannabis to tobacco and called for similar public health approaches. Discourage use. Protect bystanders. Avoid criminalization but treat the substance with clear-eyed caution.
Mechanisms remain only partly mapped. Cannabis appears to disrupt normal heart rhythm control. It can spike the heart muscle’s demand for oxygen. Endothelial dysfunction surfaces too. Blood vessels struggle to relax and widen. Blood flow suffers. One study within the meta-analysis spotted the highest heart attack danger roughly one hour after consumption. The spike fades but the cumulative toll may not.
Earlier signals pointed the same direction. A 2023 presentation at the American College of Cardiology meeting tied daily marijuana use to greater odds of coronary artery disease. A 2024 study in the Journal of the American Heart Association drew on more than 434,000 adults. Daily cannabis users showed 25 percent higher odds of heart attack and 42 percent higher odds of stroke even after adjustments for tobacco and other factors. The pattern strengthened with heavier use.
Cross-sectional work adds biological detail. A 2025 paper in JAMA Cardiology examined 55 participants. Both chronic smokers of cannabis and those using THC edibles displayed impaired vascular endothelial function. The damage mirrored what tobacco smokers experience though the pathways differed. Serum from cannabis smokers blunted nitric oxide production in lab-grown cells. Edible users showed a different profile. Either way the vessels paid a price.
Not every analysis agrees. Some veteran-focused research found no clear tie between cannabis and events in older patients already burdened by coronary disease. A 2025 study of military veterans reported no significant rise in events. Such pockets of nuance matter. They remind clinicians that age, consumption method, frequency and co-existing conditions shape the risk equation.
Yet the weight of recent evidence tilts toward concern. The retrospective TriNetX analysis published in JACC: Advances delivered absolute risks that still look small on paper. Heart attack occurred in 0.558 percent of cannabis users versus 0.09 percent of nonusers. The gap widens dramatically in relative terms for a population screened to exclude traditional risk factors. Major adverse cardiovascular events hit 1.187 percent versus 0.366 percent. All-cause mortality also ran higher.
Kamel and colleagues flagged limitations. Retrospective designs can’t prove cause and effect. Many datasets failed to capture exact dose, duration or method of cannabis intake. Polydrug use complicates the picture. Cocaine or other substances might travel with cannabis but escape full accounting. The meta-analysis faced similar hurdles when pooling disparate studies.
Even so the consistency across hundreds of millions of records demands attention. Doctors increasingly hear patients describe cannabis as harmless or even beneficial. The data suggest otherwise for the cardiovascular system. “Patients should be forthcoming with their doctors,” Kamel said. “We are their number one advocate and having the full story matters.”
Public health messaging has yet to catch up. Warnings on packaging remain rare. Many states regulate sales but say little about heart risks. The new findings could push regulators to reconsider. They could also spur more rigorous prospective trials that track users over time with better controls for confounders.
Until then cardiologists face a practical shift. Routine screening for cannabis use now looks prudent. It belongs alongside questions about smoking, diet and exercise. Younger patients in particular may not suspect their occasional edible or vape session could stress their arteries. The risk may compound quietly until an event occurs.
Research continues to accumulate. A UCLA Health summary from August 2025 noted reduced vascular function among regular edible users exceeding 55 percent compared with nonusers. Another analysis tied heavier monthly use to progressively worse odds. The dose-response relationship strengthens the case for a direct biological effect.
Industry insiders in both health care and cannabis businesses watch closely. Legal markets have boomed. Billions flow through regulated channels. If clearer warnings and updated clinical guidelines follow this wave of studies, prescribing patterns, insurance coverage and consumer behavior could shift. Hospitals may see more young heart patients disclosing cannabis history. Prevention programs might expand screening and education.
The evidence doesn’t outlaw cannabis. It does argue for informed consent. Adults can still choose. They should do so with eyes open to the cardiac price tag. For those already managing hypertension, diabetes or other risks the added burden looks especially unwise.
Science moves methodically. Each new paper refines the picture. The 2025 retrospective study and its companion meta-analysis mark a notable escalation in scale and focus on younger, otherwise healthy users. The June Heart meta-analysis broadens the lens to mortality. Together they paint a coherent warning.
Physicians now hold stronger language when counseling patients. Researchers gain clearer targets for future work. Policy makers receive fresh data to weigh against liberalization trends. And millions of users gain information that could alter their habits before damage sets in.
The heart, after all, keeps its own quiet score. Cannabis may feel light on the lungs or mind. On the cardiovascular system its impact lands heavier than many assumed. The numbers don’t lie. They simply wait for society to catch up.
WebProNews is an iEntry Publication